Connect Biopharma Holdings Limited Sponsored ADR

CNTB Healthcare Biotechnology

Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.91 0.00 0.00%
Market cap
$57.1M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
n/a
Altman Z
−5.94
Beneish M
681.78
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
62.51 48.75 156.81 267.72 152.42 118.30 93.71 44.34
Receivables
— — 5.16 7.41 3.36 4.25 3.25 6.59
Other current assets
2.41 3.33 — — — — — —
Total current assets
64.92 52.09 161.97 275.13 155.78 122.55 96.96 50.93
Property, Plant, Equpment (Net)
0.46 0.49 1.06 9.31 4.98 4.27 4.05 3.81
Long-Term Investments
— — — — 9.44 — — —
Goodwill and Intangible Assets (Total)
— — 0.05 0.09 0.07 0.06 0.05 0.05
Long-term assets (Other)
0.69 0.91 3.04 2.95 0.25 0.02 0.03 0.65
Total non-current assets
— — 4.30 15.92 18.23 4.82 4.32 5.15
Total Assets
66.07 53.49 166.27 291.05 174.01 127.38 101.28 56.08
Accounts Payable
0.50 3.27 3.78 12.74 11.94 2.21 0.34 1.96
Accrued Expenses
— — — — — 9.48 7.80 11.16
Current Part of Debt
0.06 0.06 — — — — — —
Current Part of Capital Lease
— — 0.09 0.10 0.19 0.29 0.15 0.32
Other current liabilities
0.36 0.60 1.95 5.15 3.51 13.32 0.16 0.17
Total current liabilities
0.92 3.93 5.82 17.99 15.62 25.29 8.46 13.61
Long Term Debt (Total)
83.66 92.38 0.05 0.03 0.25 0.18 0.02 0.37
Non-current Revenue (Deferred)
— — — 0.78 0.65 — — —
Non-current Liabilities (Other)
— — 317.48 — — 0.41 0.63 0.11
Total non-current liabilities
— — 317.52 0.81 0.90 0.59 0.66 0.48
Total liabilities
84.58 96.31 323.35 18.80 16.52 25.88 9.12 14.10
Additional Paid In Capital
— — 6.36 642.19 628.66 432.40 439.36 444.18
Common Stock (Net)
0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01
Retained Earnings
(17.99) (41.94) (164.19) (373.00) (479.84) (329.73) (345.35) (400.83)
Treasury Stock
— — — 0.18 0.18 0.18 0.18 0.18
Shareholders Equity (Other)
— — 0.75 3.24 8.85 11.85 — —
Common Equity (Total)
(18.51) (42.82) (157.08) 272.26 157.49 101.50 92.17 41.98
Shareholders Equity (Total)
(18.51) (42.82) (157.08) 272.26 157.49 101.50 92.17 41.98
Shareholders Equity and Liabilities (Total)
— — 166.27 291.05 174.01 127.38 101.28 56.08
Shares (Common)
— — 34.20 55.08 55.04 55.10 55.35 56.44
Shareholders Equity (Tangible)
— — (157.13) 272.17 157.42 101.44 92.11 41.94
Net Debt
21.21 43.68 (156.76) (267.69) (152.17) (118.12) (93.68) (43.97)
Total Debt
83.72 92.44 0.05 0.03 0.25 0.18 0.02 0.37

Fold the line items

In millions of $ except per-share values · columns are period end dates